Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raju Subramanian

Showing results (31-40 of 76) with videos related to

Pageof 8
Sort By:
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 19, 2012
Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidateXiaochun Zhu, J Greg Slatter, Maurice G Emery, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 20, 2004
In vitro and in vivo metabolism of a potent and selective integrin alpha v beta 3 antagonist in rats, dogs, and monkeysDonghui Cui, Raju Subramanian, Magang Shou, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 22, 2022
Human and nonclinical disposition of [<sup>14</sup>C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infectionRaju Subramanian, John Ling, Jianhong Wang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 27, 2010
Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interactionSimon G Wong, Peter W Fan, Raju Subramanian, et al.
Clinical Pharmacokinetics|January 18, 2024
Pharmacokinetics, Disposition, and Biotransformation of [<sup>14</sup>C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous InfusionElijah Weber, Raju Subramanian, William Rowe, et al.
Journal of Clinical Pharmacology|March 14, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on HemodialysisBenjamin Wu, Murad Melhem, Raju Subramanian, et al.
Clinical Pharmacokinetics|August 13, 2016
Pharmacokinetics, Biotransformation, and Excretion of [<sup>14</sup>C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on HemodialysisRaju Subramanian, Xiaochun Zhu, M Benjamin Hock, et al.
Analytical Chemistry|November 17, 2025
Hydrogen/Deuterium Exchange for Chiral Stability Assessment in Acidic Methine-Containing CompoundsZaikuan Josh Yu, Cristobal Morfin, Thomas Paul, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 23, 2003
Bioactivation of the 3-amino-6-chloropyrazinone ring in a thrombin inhibitor leads to novel dihydro-imidazole and imidazolidine derivatives: structures and mechanism using 13C-labels, mass spectrometry, and NMRRaju Subramanian, Charles C Lin, Jonathan Z Ho, et al.
Journal of Immunotoxicology|July 4, 2014
Inhibition of CRAC with a human anti-ORAI1 monoclonal antibody inhibits T-cell-derived cytokine production but fails to inhibit a T-cell-dependent antibody response in the cynomolgus monkeyKevin Gaida, Hossein Salimi-Moosavi, Raju Subramanian, et al.
Pageof 8

Showing results (31-40 of 76) with videos related to

Sort By:
Pageof 8
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 19, 2012
Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidateXiaochun Zhu, J Greg Slatter, Maurice G Emery, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 20, 2004
In vitro and in vivo metabolism of a potent and selective integrin alpha v beta 3 antagonist in rats, dogs, and monkeysDonghui Cui, Raju Subramanian, Magang Shou, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 22, 2022
Human and nonclinical disposition of [<sup>14</sup>C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infectionRaju Subramanian, John Ling, Jianhong Wang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 27, 2010
Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interactionSimon G Wong, Peter W Fan, Raju Subramanian, et al.
Clinical Pharmacokinetics|January 18, 2024
Pharmacokinetics, Disposition, and Biotransformation of [<sup>14</sup>C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous InfusionElijah Weber, Raju Subramanian, William Rowe, et al.
Journal of Clinical Pharmacology|March 14, 2018
Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on HemodialysisBenjamin Wu, Murad Melhem, Raju Subramanian, et al.
Clinical Pharmacokinetics|August 13, 2016
Pharmacokinetics, Biotransformation, and Excretion of [<sup>14</sup>C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on HemodialysisRaju Subramanian, Xiaochun Zhu, M Benjamin Hock, et al.
Analytical Chemistry|November 17, 2025
Hydrogen/Deuterium Exchange for Chiral Stability Assessment in Acidic Methine-Containing CompoundsZaikuan Josh Yu, Cristobal Morfin, Thomas Paul, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 23, 2003
Bioactivation of the 3-amino-6-chloropyrazinone ring in a thrombin inhibitor leads to novel dihydro-imidazole and imidazolidine derivatives: structures and mechanism using 13C-labels, mass spectrometry, and NMRRaju Subramanian, Charles C Lin, Jonathan Z Ho, et al.
Journal of Immunotoxicology|July 4, 2014
Inhibition of CRAC with a human anti-ORAI1 monoclonal antibody inhibits T-cell-derived cytokine production but fails to inhibit a T-cell-dependent antibody response in the cynomolgus monkeyKevin Gaida, Hossein Salimi-Moosavi, Raju Subramanian, et al.
Pageof 8